{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:49Z","timestamp":1786480249895,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"HHS | National Institutes of Health","award":["Z99 DE999999"],"award-info":[{"award-number":["Z99 DE999999"]}]},{"name":"HHS | NIH | Office of Extramural Research, National Institutes of Health","award":["DK097053"],"award-info":[{"award-number":["DK097053"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-20-CE14-0024-01 to G.L.)"],"award-info":[{"award-number":["ANR-20-CE14-0024-01 to G.L.)"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fondation de la Recherche Medicale","award":["DEQ20180339193"],"award-info":[{"award-number":["DEQ20180339193"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The entire extracellular domain of thrombospondin type-1 domain 7A (THSD7A) in the luciferase immunoprecipitation system immunoassay was required to detect autoantibodies with high sensitivity in membranous nephropathy (MN).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In THSD7A-seropositive MN patients, changes in antibody levels precede changes in clinical status.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Seropositive THSD7A antibodies were detected in some patients with MN considered to be secondary to autoimmunity or cancer.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pathogenic autoantibodies against thrombospondin type-1 domain 7A (THSD7A) are present in approximately 3% of patients with membranous nephropathy (MN). Compared with PLA2R antibodies, less is known about THSD7A autoantibodies (ABs) because of the relative rarity and the lack of a commercially available quantitative immunoassay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we describe the development and validation of a highly quantitative luciferase immunoprecipitation system (LIPS) assay for detecting THSD7A ABs and used it to study dominant THSD7A epitopes, disease associations, and monitoring disease activity. The Department of Defense Serum Repository (DODSR) was then used to analyze THSD7A AB in 371 longitudinal serum samples collected before clinical diagnosis of MN from 110 PLA2R-negative MN subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LIPS analysis demonstrated that a near full-length THSD7A (amino acids 1\u20131656) detected robust autoantibody levels in all known seropositive MN patients with 100% sensitivity and specificity compared with ELISA and\/or Western blotting. Most of the THSD7A-seropositive subjects in our pilot cohort had evidence of coexisting autoimmunity or cancer. Moreover, three THSD7A-seropositive patients undergoing immunosuppressive therapy showed longitudinal autoantibody levels that tracked clinical status. Additional epitope analysis of two smaller protein THSD7A fragments spanning amino acids 1-416 and 1-671 demonstrated lower sensitivity of 32% and 44%, respectively. In the DODSR cohort, THSD7A seropositivity was detected in 4.5% of PLA2R-negative MN patients. In one primary and in one secondary MN-associated with cancer, THSD7A ABs were detectable &lt;1 month before biopsy-proven diagnosis. In addition, three patients with lupus membranous nephropathy had detectable THSD7A ABs years before hypoalbuminemia and biopsy-proven diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although further studies are needed to explore the significance of THSD7A ABs in lupus membranous nephropathy, this study describes a novel, highly sensitive LIPS immunoassay for detecting THSD7A ABs and adds to the existing literature on THSD7A-associated MN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number:<\/jats:title>\n                    <jats:p>NCT00977977; registration date: September 16, 2009.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0005112022","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T01:40:29Z","timestamp":1669772429000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Prediagnostic Appearance of Thrombospondin Type-1 Domain 7A Autoantibodies in Membranous Nephropathy"],"prefix":"10.34067","volume":"4","author":[{"given":"Peter D.","family":"Burbelo","sequence":"first","affiliation":[{"name":"National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Olson","sequence":"additional","affiliation":[{"name":"Nephrology Department, Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Keller","sequence":"additional","affiliation":[{"name":"National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Joshi","sequence":"additional","affiliation":[{"name":"Nephrology Department, Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella M.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Jen","family":"Chuang","sequence":"additional","affiliation":[{"name":"School of Medicine, National Tsing Hua University, Hsinchu, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Lambeau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d'Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Mol\u00e9culaire et Cellulaire, Valbonne Sophia Antipolis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Nephrology, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Waldman","sequence":"additional","affiliation":[{"name":"Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"6","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B2-20250823","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey","volume":"56","author":"Glassock","year":"2010","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MNH.0000000000000697","article-title":"Membranous nephropathy: current understanding of various causes in light of new target antigens","volume":"30","author":"Ronco","year":"2021","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"1","key":"B4-20250823","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"issue":"24","key":"B5-20250823","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"issue":"3","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Zaghrini","year":"2019","journal-title":"Kidney Int."},{"issue":"1","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/0886022X.2018.1456457","article-title":"An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN","volume":"40","author":"Ren","year":"2018","journal-title":"Ren Fail."},{"issue":"2","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"16188","DOI":"10.1038\/s41598-021-94921-y","article-title":"Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy","volume":"11","author":"Reinhard","year":"2021","journal-title":"Sci Rep."},{"issue":"2","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B11-20250823","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jim.2017.02.001","article-title":"Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy","volume":"444","author":"Burbelo","year":"2017","journal-title":"J Immunol Methods."},{"issue":"1","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B13-20250823","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcp.21990","article-title":"Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation","volume":"222","author":"Wang","year":"2010","journal-title":"J Cell Physiol."},{"key":"B14-20250823","first-page":"1549","article-title":"Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS)","volume":"32","author":"Burbelo","year":"2009","journal-title":"J Vis Exp."},{"issue":"2","key":"B15-20250823","doi-asserted-by":"crossref","first-page":"e32001","DOI":"10.1371\/journal.pone.0032001","article-title":"Two major autoantibody clusters in systemic lupus erythematosus","volume":"7","author":"Ching","year":"2012","journal-title":"PLoS One."},{"issue":"5","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1681\/ASN.2017070805","article-title":"The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2215\/CJN.01460217","article-title":"Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B18-20250823","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.12659\/MSM.909815","article-title":"Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: a single center retrospective study from China","volume":"24","author":"Zhang","year":"2018","journal-title":"Med Sci Monit."},{"issue":"5","key":"B19-20250823","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2020.04.013","article-title":"Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study","volume":"76","author":"Hanset","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.ajkd.2018.10.009","article-title":"VEGF-A links angiolymphoid hyperplasia with eosinophilia (ALHE) to THSD7A membranous nephropathy: a report of 2 cases","volume":"73","author":"Matsumoto","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B21-20250823","doi-asserted-by":"crossref","first-page":"619147","DOI":"10.3389\/fimmu.2021.619147","article-title":"Case report: THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol."},{"issue":"3","key":"B22-20250823","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/annrheumdis-2019-215918","article-title":"Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20","volume":"79","author":"Schwartz","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2017-212403","article-title":"A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease","volume":"77","author":"Aeschlimann","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"B24-20250823","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12882-016-0407-3","article-title":"PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy","volume":"17","author":"Ge","year":"2016","journal-title":"BMC Nephrol."},{"issue":"18","key":"B25-20250823","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2169\/internalmedicine.55.6726","article-title":"Membranous nephropathy with an enhanced granular expression of thrombospondin type-1 domain-containing 7A in a pregnant woman","volume":"55","author":"Iwakura","year":"2016","journal-title":"Intern Med."},{"issue":"8","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.34067\/KID.0001492021","article-title":"Transforming growth factor beta receptor 3 (TGFBR3)-associated membranous nephropathy","volume":"2","author":"Caza","year":"2021","journal-title":"Kidney360."},{"issue":"1","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"B28-20250823","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes","volume":"32","author":"Ravindran","year":"2021","journal-title":"J Am Soc Nephrol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0005112022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:00:06Z","timestamp":1786478406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0005112022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0005112022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"2022-08-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}